Vitamin D Deficiency is a global public health concern worldwide. Vitamin D, which is not only a nutrient but mainly a hormone synthesised in our body with the help of sunlight, has long been recognised as essential to the skeleton system. Growing evidence suggests that it also plays a major role for our immune system, which is particularly relevant in a period of viral pandemic.
Cole Pharmaceuticals is addressing the problem of vitamin D deficiency by providing patients with user-friendly formulations and delivery technologies aiming at giving them a compliant and pleasurable experience. Our formulations are particularly suitable for patients suffering from dysphagia and malabsorption.
Cole Pharmaceuticals was created with the ambition to become the first pharmaceutical company dedicated to the reduction of vitamin D deficiency, which is a worldwide public health problem.
It always starts with a dream and an idea!
- 2014: This is what happened when both cofounders Claude Lubicki and Jean-Marie Vandeplas met for the first time back. Claude and Jean-Marie wanted to address vitamin D deficiency, a growing public health issue from the angle of addressing the need for vitamin D supplementation for patients suffering from dysphagia and/or malabsorption.
Cole Pharmaceuticals was created with the ambition to become the first pharmaceutical company dedicated to the reduction of vitamin D deficiency, which is a worldwide public health problem. In addition, both entrepreneurs were keen to improve Women's Health in all of its aspects and throughout all stages of life.
- 2017: The Company was established In Belgium
- 2019: The Company had a portfolio of daily-dosing vitamin D3 and successfully fund raised. The company is now backed by private investors.
- 2020: Despite the exceptional circumstances of the pandemic COVID-19, the company is operating with a direct presence in BELUX and Partnering abroad.